Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma
Epithelioid sarcoma (ES) is a rare soft tissue sarcoma with an incidence of 0.05 per 100,000 population in the USA. It is characterized by multiple local recurrences and regional lymph nodes form the commonest site of metastases. The function of Integrase Inhibitor 1 (INI1) protein is lost in more t...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-04-01
|
| Series: | Future Science OA |
| Subjects: | |
| Online Access: | https://www.future-science.com/doi/10.2144/fsoa-2020-0173 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850153135201320960 |
|---|---|
| author | Ghazal Tansir Sameer Rastogi Shamim Ahmed Shamim Adarsh Barwad |
| author_facet | Ghazal Tansir Sameer Rastogi Shamim Ahmed Shamim Adarsh Barwad |
| author_sort | Ghazal Tansir |
| collection | DOAJ |
| description | Epithelioid sarcoma (ES) is a rare soft tissue sarcoma with an incidence of 0.05 per 100,000 population in the USA. It is characterized by multiple local recurrences and regional lymph nodes form the commonest site of metastases. The function of Integrase Inhibitor 1 (INI1) protein is lost in more than 90% of cases, which was the basis for the introduction of tazemetostat into the therapeutic armamentarium for management of advanced ES. The efficacy and manageable toxicity profile of tazemetostat have been demonstrated recently, leading to its accelerated approval for treatment of advanced ES. We report one of the first real-world cases of relapsed, metastatic ES treated with tazemetostat. The patient attained partial response with the therapy and is tolerating the drug well without serious toxicities. |
| format | Article |
| id | doaj-art-bf3fb7ce6d1045d98745bdef18f4eced |
| institution | OA Journals |
| issn | 2056-5623 |
| language | English |
| publishDate | 2021-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Future Science OA |
| spelling | doaj-art-bf3fb7ce6d1045d98745bdef18f4eced2025-08-20T02:25:48ZengTaylor & Francis GroupFuture Science OA2056-56232021-04-017410.2144/fsoa-2020-0173Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcomaGhazal Tansir0Sameer Rastogi1Shamim Ahmed Shamim2Adarsh Barwad31Sarcoma Medical Oncology Clinic, BRA IRCH, All India Institute of Medical Sciences, New Delhi, India1Sarcoma Medical Oncology Clinic, BRA IRCH, All India Institute of Medical Sciences, New Delhi, India2Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India3Department of Pathology, All India Institute of Medical Sciences, New Delhi, IndiaEpithelioid sarcoma (ES) is a rare soft tissue sarcoma with an incidence of 0.05 per 100,000 population in the USA. It is characterized by multiple local recurrences and regional lymph nodes form the commonest site of metastases. The function of Integrase Inhibitor 1 (INI1) protein is lost in more than 90% of cases, which was the basis for the introduction of tazemetostat into the therapeutic armamentarium for management of advanced ES. The efficacy and manageable toxicity profile of tazemetostat have been demonstrated recently, leading to its accelerated approval for treatment of advanced ES. We report one of the first real-world cases of relapsed, metastatic ES treated with tazemetostat. The patient attained partial response with the therapy and is tolerating the drug well without serious toxicities.https://www.future-science.com/doi/10.2144/fsoa-2020-0173epigeneticsepithelioid sarcomapersonalized medicinetargeted therapytazemetostat |
| spellingShingle | Ghazal Tansir Sameer Rastogi Shamim Ahmed Shamim Adarsh Barwad Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma Future Science OA epigenetics epithelioid sarcoma personalized medicine targeted therapy tazemetostat |
| title | Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma |
| title_full | Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma |
| title_fullStr | Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma |
| title_full_unstemmed | Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma |
| title_short | Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma |
| title_sort | early clinical and metabolic response to tazemetostat in advanced relapsed ini1 negative epithelioid sarcoma |
| topic | epigenetics epithelioid sarcoma personalized medicine targeted therapy tazemetostat |
| url | https://www.future-science.com/doi/10.2144/fsoa-2020-0173 |
| work_keys_str_mv | AT ghazaltansir earlyclinicalandmetabolicresponsetotazemetostatinadvancedrelapsedini1negativeepithelioidsarcoma AT sameerrastogi earlyclinicalandmetabolicresponsetotazemetostatinadvancedrelapsedini1negativeepithelioidsarcoma AT shamimahmedshamim earlyclinicalandmetabolicresponsetotazemetostatinadvancedrelapsedini1negativeepithelioidsarcoma AT adarshbarwad earlyclinicalandmetabolicresponsetotazemetostatinadvancedrelapsedini1negativeepithelioidsarcoma |